11 Best High Volume Penny Stocks to Buy Now

Page 5 of 5

6. Esperion Therapeutics, Inc. (NASDAQ:ESPR)

On March 16, 2026, Esperion highlighted the inclusion of bempedoic acid in the 2026 American College of Cardiology/American Heart Association Multisociety Guideline on the Management of Dyslipidemia. The guidelines support the use of bempedoic acid across multiple patient groups to lower LDL-C and reduce cardiovascular risk, particularly in patients who cannot tolerate statins or are unable to reach target levels. Christie Ballantyne said the update reflects the importance of “earlier, aggressive combination therapy” and recognizes statin intolerance as a key challenge, pointing to broader use of additional therapies to improve long-term outcomes.

On March 13, 2026, Citizens raised the price target on Esperion Therapeutics, Inc. (NASDAQ:ESPR) to $5 from $4 and maintained an Outperform rating. Citizens said Esperion’s Q4 results were consistent with its January preannouncement and pointed to continued execution of its Vision 2040 strategy, including the acquisition of Corstasis Therapeutics and progress in advancing ESP-2001.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) develops and commercializes treatments for patients with elevated low-density lipoprotein cholesterol in the United States.

While we acknowledge the potential of ESPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ESPR and that has 100x upside potential, check out our report about this cheapest AI stock.

Click to continue reading and see the 5 Best High Volume Penny Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.

Page 5 of 5